Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22
Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/06/22
Intercept Pharma Scores $450 Million Deal For Its Flagship Liver DrugInvestors Business Daily • 05/05/22
Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent PaymentsGlobeNewsWire • 05/05/22
Intercept (ICPT) Outperforms Industry in 3 Months: What Lies Ahead?Zacks Investment Research • 04/22/22
Intercept (ICPT) Up 15.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 04/01/22
Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASHSeeking Alpha • 03/05/22
Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/02/22
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results, Issues 2022 Financial Guidance and Provides Business UpdateGlobeNewsWire • 03/02/22
Intercept to Announce Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022GlobeNewsWire • 02/23/22
4 Under-the-Radar Stocks With 319% to 645% Upside in 2022, According to Wall StreetThe Motley Fool • 01/29/22
Pomerantz Law Firm Announces the Filing of a Class Action against Intercept Pharmaceuticals, Inc. and Certain Officers - ICPTPRNewsWire • 01/06/22
Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASHGlobeNewsWire • 12/20/21